{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T22:31:13Z","timestamp":1774045873901,"version":"3.50.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mallinckrodt"},{"name":"Intercept"},{"name":"Conatus"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.cld.2018.12.010","type":"journal-article","created":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T01:25:25Z","timestamp":1551489925000},"page":"293-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Hepatic Manifestations of Lymphoproliferative Disorders"],"prefix":"10.1016","volume":"23","author":[{"given":"Chalermrat","family":"Bunchorntavakul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Rajender","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cld.2018.12.010_bib1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.path.2018.02.003","article-title":"Hepatic lymphoma diagnosis","volume":"11","author":"Choi","year":"2018","journal-title":"Surg Pathol Clin"},{"issue":"3","key":"10.1016\/j.cld.2018.12.010_bib2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s12288-013-0263-2","article-title":"Primary hepatic lymphoma: dilemmas in diagnostic approach and therapeutic management","volume":"30","author":"Mastoraki","year":"2014","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"47","key":"10.1016\/j.cld.2018.12.010_bib3","first-page":"6016","article-title":"Diagnosis and surgical treatment of primary hepatic lymphoma","volume":"16","author":"Yang","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"3\u20134","key":"10.1016\/j.cld.2018.12.010_bib4","first-page":"293","article-title":"Primary non-Hodgkin's lymphoma of the liver","volume":"29","author":"Lei","year":"1998","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.cld.2018.12.010_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cld.2010.09.013","article-title":"Hematologic and oncologic diseases and the liver","volume":"15","author":"Singh","year":"2011","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2018.12.010_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2559.2008.03069.x","article-title":"Patterns of liver infiltration in lymphoproliferative disease","volume":"53","author":"Baumhoer","year":"2008","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.cld.2018.12.010_bib7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.bpg.2013.06.012","article-title":"Liver in haematological disorders","volume":"27","author":"Pieri","year":"2013","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2018.12.010_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.clinre.2014.11.001","article-title":"Diagnostic imaging of hepatic lymphoma","volume":"39","author":"Abe","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2018.12.010_bib9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00428-012-1199-x","article-title":"Etiological factors in primary hepatic B-cell lymphoma","volume":"460","author":"Kikuma","year":"2012","journal-title":"Virchows Arch"},{"issue":"8","key":"10.1016\/j.cld.2018.12.010_bib10","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/1097-0142(20011015)92:8<2023::AID-CNCR1540>3.0.CO;2-B","article-title":"Primary hepatic lymphoma: favorable outcome after combination chemotherapy","volume":"92","author":"Page","year":"2001","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.cld.2018.12.010_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1600-0609.2008.01081.x","article-title":"Excellent prognosis and prevalence of HCV infection of primary hepatic and splenic non-Hodgkin's lymphoma","volume":"81","author":"De Renzo","year":"2008","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.cld.2018.12.010_bib12","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.7863\/jum.2010.29.9.1353","article-title":"Role of contrast-enhanced ultrasonography in primary hepatic lymphoma","volume":"29","author":"Foschi","year":"2010","journal-title":"J\u00a0Ultrasound Med"},{"issue":"9","key":"10.1016\/j.cld.2018.12.010_bib13","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1007\/s00261-018-1476-5","article-title":"MRI features of primary hepatic lymphoma","volume":"43","author":"Colagrande","year":"2018","journal-title":"Abdom Radiol (NY)"},{"issue":"3","key":"10.1016\/j.cld.2018.12.010_bib14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4103\/0019-509X.52960","article-title":"Positron emission tomography\/computerized tomography evaluation of primary Hodgkin's disease of liver","volume":"46","author":"Gota","year":"2009","journal-title":"Indian J Cancer"},{"issue":"10053","key":"10.1016\/j.cld.2018.12.010_bib15","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cld.2018.12.010_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.semradonc.2009.09.006","article-title":"Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects","volume":"20","author":"Punnett","year":"2010","journal-title":"Semin Radiat Oncol"},{"issue":"5","key":"10.1016\/j.cld.2018.12.010_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0277-5379(82)90109-2","article-title":"The liver in Hodgkin's disease\u2013I. Clinico-pathological relations","volume":"18","author":"Brinckmeyer","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"4","key":"10.1016\/j.cld.2018.12.010_bib18","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/gut.42.4.576","article-title":"Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases","volume":"42","author":"Rowbotham","year":"1998","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cld.2018.12.010_bib19","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3748\/wjg.v23.i2.366","article-title":"Vanishing bile duct syndrome in Hodgkin's lymphoma: a case report and literature review","volume":"23","author":"Bakhit","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2018.12.010_bib20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cld.2007.11.007","article-title":"Vanishing bile duct syndrome","volume":"12","author":"Reau","year":"2008","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cld.2018.12.010_bib21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1186\/1756-0500-7-529","article-title":"Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature","volume":"7","author":"Rota Scalabrini","year":"2014","journal-title":"BMC Res Notes"},{"issue":"2","key":"10.1016\/j.cld.2018.12.010_bib22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-0676.1987.tb00320.x","article-title":"Hepatic sinusoidal dilatation in Hodgkin's disease","volume":"7","author":"Bruguera","year":"1987","journal-title":"Liver"},{"issue":"1","key":"10.1016\/j.cld.2018.12.010_bib23","first-page":"37","article-title":"Vanishing bile duct syndromes: considerations of the immunobiology of autoimmune biliary diseases","volume":"1","author":"Reynoso-Paz","year":"1999","journal-title":"Isr Med Assoc J"},{"issue":"7","key":"10.1016\/j.cld.2018.12.010_bib24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.urolonc.2018.01.019","article-title":"Stauffer's syndrome: a comprehensive review and proposed updated diagnostic criteria","volume":"36","author":"Fontes-Sousa","year":"2018","journal-title":"Urol Oncol"},{"issue":"12","key":"10.1016\/j.cld.2018.12.010_bib25","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/MPH.0b013e31818b37c4","article-title":"Vanishing bile duct syndrome and Hodgkin disease: a case series and review of the literature","volume":"30","author":"Pass","year":"2008","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"12a","key":"10.1016\/j.cld.2018.12.010_bib26","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/imj.12609","article-title":"Vanishing bile duct syndrome and immunodeficiency preceding the diagnosis of Hodgkin lymphoma","volume":"44","author":"Yeh","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.cld.2018.12.010_bib27","doi-asserted-by":"crossref","first-page":"k3204","DOI":"10.1136\/bmj.k3204","article-title":"Non-Hodgkin lymphoma","volume":"362","author":"Bowzyk Al-Naeeb","year":"2018","journal-title":"BMJ"},{"issue":"26","key":"10.1016\/j.cld.2018.12.010_bib28","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.3748\/wjg.14.4111","article-title":"Liver in systemic disease","volume":"14","author":"Shimizu","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2018.12.010_bib29","first-page":"440","article-title":"The diagnostic value of percutaneus liver biopsy in patients with non Hodgkin's lymphoma - a preliminary report","volume":"24","author":"Kolaric","year":"1977","journal-title":"Acta hepato-gastroenterologica"},{"issue":"1","key":"10.1016\/j.cld.2018.12.010_bib30","first-page":"13","article-title":"Histologic and cytologic liver changes induced by cytostatic drugs in 32 patients with non-Hodgkin's lymphomas","volume":"33","author":"Roth","year":"1979","journal-title":"Acta Med Iugosl"},{"issue":"4","key":"10.1016\/j.cld.2018.12.010_bib31","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/1097-0142(197304)31:4<840::AID-CNCR2820310412>3.0.CO;2-W","article-title":"Diagnosis of liver involvement by lymphoma: results in 96 consecutive peritoneoscopies","volume":"31","author":"Bagley","year":"1973","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.cld.2018.12.010_bib32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2559.1995.tb00192.x","article-title":"Pathology of the liver in leukaemia and lymphoma. A study of 110 autopsies","volume":"26","author":"Scheimberg","year":"1995","journal-title":"Histopathology"},{"issue":"7","key":"10.1016\/j.cld.2018.12.010_bib33","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1111\/j.1572-0241.2003.07536.x","article-title":"Clinical features of non-Hodgkins lymphoma presenting with acute liver failure: a report of five cases and review of published experience","volume":"98","author":"Lettieri","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.cld.2018.12.010_bib34","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1097\/00042737-200110000-00019","article-title":"Acute liver failure as the sole manifestation of relapsing non-Hodgkin's lymphoma","volume":"13","author":"Morali","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2018.12.010_bib35","first-page":"774","article-title":"Acute liver failure due to non-Hodgkin's lymphoma","volume":"88","author":"Salo","year":"1993","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2018.12.010_bib36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1440-1827.2007.02201.x","article-title":"Submassive hepatocellular necrosis associated with infiltration by peripheral T-cell lymphoma of cytotoxic phenotype: report of two cases","volume":"58","author":"Ohtani","year":"2008","journal-title":"Pathol Int"},{"issue":"6","key":"10.1016\/j.cld.2018.12.010_bib37","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1200\/JCO.1987.5.6.969","article-title":"Biliary tract obstruction secondary to cancer: management guidelines and selected literature review","volume":"5","author":"Lokich","year":"1987","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cld.2018.12.010_bib38","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijscr.2018.02.038","article-title":"Obstructive jaundice as primary presentation of a stage IIE Non-Hodgkin lymphoma: a decision making process between advanced lymphoma and locally advanced\/metastatic pancreatic adenocarcinoma","volume":"44","author":"Blouhos","year":"2018","journal-title":"Int J Surg Case Rep"},{"issue":"1","key":"10.1016\/j.cld.2018.12.010_bib39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.asjsur.2013.09.009","article-title":"Primary non-Hodgkin's lymphoma of the common bile duct: a case report and literature review","volume":"40","author":"Zakaria","year":"2017","journal-title":"Asian J Surg"},{"issue":"1","key":"10.1016\/j.cld.2018.12.010_bib40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s13244-017-0585-y","article-title":"CT imaging of primary pancreatic lymphoma: experience from three referral centres for pancreatic diseases","volume":"9","author":"Boninsegna","year":"2018","journal-title":"Insights Imaging"},{"issue":"5","key":"10.1016\/j.cld.2018.12.010_bib41","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.dld.2013.12.016","article-title":"Frequency of occurrence and characteristics of primary pancreatic lymphoma during endoscopic ultrasound guided fine needle aspiration: a retrospective study","volume":"46","author":"Ramesh","year":"2014","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.cld.2018.12.010_bib42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/107327481402100406","article-title":"Hereditary and acquired hemophagocytic lymphohistiocytosis","volume":"21","author":"Zhang","year":"2014","journal-title":"Cancer Control"},{"issue":"35","key":"10.1016\/j.cld.2018.12.010_bib43","doi-asserted-by":"crossref","first-page":"59977","DOI":"10.18632\/oncotarget.19230","article-title":"A\u00a0systematic review of malignancy-associated hemophagocytic lymphohistiocytosis that needs more attentions","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.cld.2018.12.010_bib44","first-page":"1275","article-title":"Lymphoma associated hemophagocytic syndrome: a single-center retrospective study","volume":"16","author":"Chang","year":"2018","journal-title":"Oncol Lett"},{"issue":"3","key":"10.1016\/j.cld.2018.12.010_bib45","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0002-9270(00)02425-4","article-title":"Hepatic manifestations of hemophagocytic syndrome: a study of 30 cases","volume":"96","author":"de Kerguenec","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.cld.2018.12.010_bib46","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00277-007-0278-6","article-title":"Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome","volume":"86","author":"Han","year":"2007","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.cld.2018.12.010_bib47","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.3109\/10428194.2013.876629","article-title":"Clinical features and treatment of natural killer\/T cell lymphoma associated with hemophagocytic syndrome: comparison with other T\u00a0cell lymphoma associated with hemophagocytic syndrome","volume":"55","author":"Han","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.cld.2018.12.010_bib48","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"issue":"5 Pt 1","key":"10.1016\/j.cld.2018.12.010_bib49","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1600-6143.2006.01294.x","article-title":"Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival","volume":"6","author":"Kremers","year":"2006","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.cld.2018.12.010_bib50","first-page":"248","article-title":"Post-transplantation lymphoproliferative disorder with gastrointestinal involvement","volume":"31","author":"Inayat","year":"2018","journal-title":"Ann Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2018.12.010_bib51","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MOT.0b013e3283465715","article-title":"Posttransplant lymphoproliferative disease following liver transplantation","volume":"16","author":"Kamdar","year":"2011","journal-title":"Curr Opin Organ Transplant"},{"issue":"5","key":"10.1016\/j.cld.2018.12.010_bib52","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/jclinpath-2012-201139","article-title":"Post-transplant lymphoproliferative disorders in liver transplant recipients: a clinicopathological study","volume":"66","author":"Lo","year":"2013","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.cld.2018.12.010_bib53","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","first-page":"453","article-title":"Post-transplant lymphoproliferative disorders","author":"Swerdlow","year":"2017"},{"issue":"2","key":"10.1016\/j.cld.2018.12.010_bib54","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.cld.2018.12.010_bib55","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2141.2010.08160.x","article-title":"Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines","volume":"149","author":"Parker","year":"2010","journal-title":"Br J Haematol"},{"issue":"Suppl 4","key":"10.1016\/j.cld.2018.12.010_bib56","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.1093\/cid\/ciw043","article-title":"Hepatitis B virus reactivation in the setting of cancer chemotherapy and other immunosuppressive drug therapy","volume":"62","author":"Gonzalez","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.cld.2018.12.010_bib57","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/hep.27609","article-title":"Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?","volume":"61","author":"Di Bisceglie","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2018.12.010_bib58","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2018.12.010_bib59","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.cld.2018.12.010_bib60","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.cmi.2017.06.024","article-title":"Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review","volume":"23","author":"Gentile","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.cld.2018.12.010_bib61","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cld.2018.12.010_bib62","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.leukres.2016.09.014","article-title":"Delayed HBV reactivation in rituximab-containing chemotherapy: how long should we continue anti-virus prophylaxis or monitoring HBV-DNA?","volume":"50","author":"Nakaya","year":"2016","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.cld.2018.12.010_bib63","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2018.12.010_bib64","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1478-3231.2007.01618.x","article-title":"Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis","volume":"28","author":"Martyak","year":"2008","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.cld.2018.12.010_bib65","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/liv.12154","article-title":"Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease","volume":"33","author":"Chen","year":"2013","journal-title":"Liver Int"},{"issue":"12","key":"10.1016\/j.cld.2018.12.010_bib66","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1365-2893.2010.01386.x","article-title":"Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy","volume":"18","author":"Li","year":"2011","journal-title":"J\u00a0Viral Hepat"},{"issue":"23","key":"10.1016\/j.cld.2018.12.010_bib67","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/jama.2014.15704","article-title":"Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial","volume":"312","author":"Huang","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.cld.2018.12.010_bib68","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jhep.2012.07.031","article-title":"Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients","volume":"57","author":"Mahale","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2018.12.010_bib69","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(02)00773-8","article-title":"Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue","volume":"3","author":"Vento","year":"2002","journal-title":"Lancet Oncol"},{"issue":"8994","key":"10.1016\/j.cld.2018.12.010_bib70","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0140-6736(96)90212-3","article-title":"Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus","volume":"347","author":"Vento","year":"1996","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cld.2018.12.010_bib71","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1224::AID-CNCR23>3.0.CO;2-6","article-title":"Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies","volume":"83","author":"Zuckerman","year":"1998","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.cld.2018.12.010_bib72","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hep.29344","article-title":"Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study","volume":"67","author":"Torres","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2018.12.010_bib73","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.29414","article-title":"HCV and nonhepatic malignancy: is pre-emptive direct-acting antiviral therapy indicated prior to treatment?","volume":"67","author":"Kriss","year":"2018","journal-title":"Hepatology"},{"issue":"11\u201312","key":"10.1016\/j.cld.2018.12.010_bib74","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/apt.13825","article-title":"Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer","volume":"44","author":"Economides","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.cld.2018.12.010_bib75","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.bbmt.2015.12.010","article-title":"Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents","volume":"22","author":"Kyvernitakis","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.cld.2018.12.010_bib76","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.29364","article-title":"Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma","volume":"67","author":"Persico","year":"2018","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2018.12.010_bib77","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jvh.12518","article-title":"The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis","volume":"23","author":"Peveling-Oberhag","year":"2016","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2018.12.010_bib78","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jceh.2017.11.012","article-title":"Advances in HCV and cryoglobulinemic vasculitis in the era of DAAs: are we at the end of the road?","volume":"8","author":"Bunchorntavakul","year":"2018","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2018.12.010_bib79","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.28753","article-title":"Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia","volume":"64","author":"Gragnani","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2018.12.010_bib80","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.gastro.2017.03.006","article-title":"Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis","volume":"153","author":"Saadoun","year":"2017","journal-title":"Gastroenterology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326118301144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326118301144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:55:58Z","timestamp":1761069358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326118301144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1089326118301144"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2018.12.010","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic Manifestations of Lymphoproliferative Disorders","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2018.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}